| Heart failure
Kerendia vs Samsca
Side-by-side clinical, coverage, and cost comparison for heart failure.Deep comparison between: Kerendia vs Samsca with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsSamsca has a higher rate of injection site reactions vs Kerendia based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Samsca but not Kerendia, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Kerendia
Samsca
At A Glance
Oral
Once daily
Mineralocorticoid receptor antagonist
Oral
Daily
Vasopressin V2-receptor antagonist
Indications
- Chronic Kidney Diseases
- Diabetes Mellitus, Non-Insulin-Dependent
- Heart failure
- Chronic kidney disease stage 5
- Myocardial Infarction
- Hyponatremia
- Heart failure
- Inappropriate ADH Syndrome
Dosing
Chronic Kidney Diseases, Diabetes Mellitus, Non-Insulin-Dependent Starting dose 10 mg or 20 mg orally once daily based on eGFR and serum potassium; target dose 20 mg once daily, adjusted after 4 weeks based on serum potassium levels.
Heart failure Starting dose 10 mg or 20 mg orally once daily based on eGFR and serum potassium; target dose 20 mg or 40 mg once daily based on eGFR at initiation, adjusted after 4 weeks.
Hyponatremia, Heart failure, Inappropriate ADH Syndrome Start at 15 mg once daily; titrate at intervals >=24 hours to 30 mg once daily, then to a maximum of 60 mg once daily as needed; initiate and re-initiate in a hospital; do not administer for more than 30 days.
Contraindications
- Hypersensitivity to any component of Kerendia
- Concomitant treatment with strong CYP3A4 inhibitors
- Adrenal insufficiency
- Autosomal dominant polycystic kidney disease (ADPKD) outside of FDA-approved REMS
- Unable to sense or respond to thirst
- Hypovolemic hyponatremia
- Concomitant use of strong CYP3A inhibitors
- Anuria
- Hypersensitivity to tolvaptan or any components of the product
Adverse Reactions
Most common (>=10%) hyperkalemia
Serious hyperkalemia requiring hospitalization, renal impairment, acute kidney injury, renal failure
Postmarketing angioedema, rash, urticaria
Most common (>=5%) Thirst, dry mouth, asthenia, constipation, pollakiuria or polyuria, hyperglycemia
Serious Disseminated intravascular coagulation, intracardiac thrombus, ventricular fibrillation, ischemic colitis, diabetic ketoacidosis, rhabdomyolysis, cerebrovascular accident, pulmonary embolism, respiratory failure, deep vein thrombosis
Postmarketing Osmotic demyelination syndrome, hypernatremia, hypersensitivity reactions including anaphylactic shock and generalized rash
Pharmacology
Finerenone is a nonsteroidal, selective mineralocorticoid receptor (MR) antagonist that blocks MR-mediated sodium reabsorption and MR overactivation in epithelial (kidney) and nonepithelial (heart, blood vessels) tissues; it has high potency and selectivity for the MR with no relevant affinity for androgen, progesterone, estrogen, or glucocorticoid receptors.
Tolvaptan is a selective vasopressin V2-receptor antagonist that blocks vasopressin's renal effect, promoting free water excretion (aquaresis) and raising serum sodium concentrations without significantly affecting urinary sodium or potassium excretion.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Kerendia
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (9/12) · Qty limit (11/12)
Samsca
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (9/12)
UnitedHealthcare
Kerendia
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (6/8) · Qty limit (6/8)
Samsca
- Covered on 4 commercial plans
- PA (1/8) · Step Therapy (0/8) · Qty limit (1/8)
Humana
Kerendia
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (2/3)
Samsca
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$0/fillfill
Bayer US Patient Assistance Foundation - KerendiaCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
$0
Otsuka Patient Assistance Foundation (OPAF)Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
KerendiaView full Kerendia profile
SamscaView full Samsca profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.